BazaarBaazi

Stock · AJANTPHARM · Healthcare

AJANTPHARM share price target 2026

Support, resistance, the F&O structure and the BazaarBaazi Crack Score for AJANTA PHARMA LIMITED, refreshed every end-of-day run. A systematic, data-only read on AJANTA PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.

The verdict

BazaarBaazi reads AJANTPHARM as constructive with a Crack Score of 89/100 as of 25 Jul 2026.
Crack Score
89/ 100
High conviction

BazaarBaaziSource & method

The scanner's readScanned · scanned 24 Jul 2026

Where AJANTPHARM stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.

Scanned77 /100 setup score

Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.

Technical axis

100/100

Fundamental axis

33/100

Money flow

81/100

Result pulse · Q4 FY26

0/100

Technical evidence

price above 50DMA

price above 150DMA

price above 200DMA

50 > 150 > 200 DMA (clean stack)

uptrend frame (50 > 200 DMA)

50DMA rising

pulled back to a rising MA

orderly dip from highs

Red flags

above 200DMA (not a confirmed short-side trend)

strong accumulation tape

weak filed result (score 0.0)

Relative valuation

P/E (TTM)

40.7

P/E vs sector

+0.8%

Sector percentile

40

PEG

n/a

Scanner levels from the deterministic engine run of 2026-07-24, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.

Open the full 500-name Setup Scan.

Price target: support and resistanceComputed 25 Jul 2026

Support and resistance for AJANTPHARM are read inside the latest show; no spot was printed in the most recent editorial note.

Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.

These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the AJANTPHARM chart, refreshed every end-of-day run.

The Crack Score, and how it is built89 / 100 · High conviction

The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for AJANTPHARM, so the figure is a transparent signal rather than a vibe.

Editorial stanceLatest signed stance is bullish.+18
History consistency5 of the last 6 published verdicts held the same stance.+11
Structure qualityNo clean spot was printed in the latest note; levels are read inside the show.0
FreshnessThe desk last reviewed 4 days ago.+4
Conviction horizonThe latest read is framed on a swing horizon.+6

Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.

The F&O viewHorizon · swing

How the futures and options structure on AJANTPHARM reads right now.

Editorial directionBullish
Horizonswing

The editorial price read on AJANTPHARM is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on AJANTPHARM can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.

Why it movedLatest editorial line

The most recent BazaarBaazi read on what is driving AJANTPHARM.

Systematic read: a disclosed, data-only model on real 1-year price structure.

Read in Systematic Read on 21 Jul 2026. Why AJANTPHARM moved, the living explainer, tracks every move on one URL.

Latest filed resultsQ4 FY26

AJANTA PHARMA LIMITED's most recent quarter, parsed straight from the official BSE filing. Every figure links back to its primary source.

Q4 FY26 · ended 31 Mar 2026Consolidated, audited · filed with BSE on 5 May 2026

Result Pulse

0 / 100

Revenue

Rs 1,422 cr

Net profit

Rs 267 cr

EPS (quarter)

Rs 21.35
GrowthYoYQoQ
Revenuen/an/a
Net profitn/an/a
Net marginn/a
What BazaarBaazi readsInsufficient data
SourceOfficial BSE filing (XBRL)

Figures are the Q4 FY26 result for AJANTA PHARMA LIMITED, parsed straight from the official BSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.

See every Q4 result the desk has read.

Earnings history, every filed quarter32 quarters on record

AJANTA PHARMA LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.

AJANTPHARM official result trail

32 quarters

Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.

QuarterRevenueEPSPAT YoYPulseSource
Q4 FY26ended 31 Mar 2026 / Consolidated, auditedRs 1,422 crRs 21.35n/an/aFiling
Q3 FY26ended 31 Dec 2025 / Consolidated, auditedRs 1,375 crRs 21.91n/a58/100Filing
Q2 FY26ended 30 Sep 2025 / Consolidated, auditedRs 1,354 crRs 20.83n/an/aFiling
Q1 FY26ended 30 Jun 2025 / Consolidated, auditedRs 1,303 crRs 20.44n/a58/100Filing
Q4 FY25ended 31 Mar 2025 / Consolidated, auditedRs 1,170 crRs 18.00n/an/aFiling
Q3 FY25ended 31 Dec 2024 / Consolidated, auditedRs 1,146 crRs 18.60n/an/aFiling
Q2 FY25ended 30 Sep 2024 / Consolidated, auditedRs 1,187 crRs 17.27n/an/aFiling
Q1 FY25ended 30 Jun 2024 / Consolidated, auditedRs 1,145 crRs 19.54n/an/aFiling
Q4 FY24ended 31 Mar 2024 / Consolidated, auditedRs 1,054 crRs 16.10n/an/aFiling
Q3 FY24ended 31 Dec 2023 / Consolidated, auditedRs 1,105 crRs 16.68n/an/aFiling
Q2 FY24ended 30 Sep 2023 / Consolidated, auditedRs 1,028 crRs 15.51n/an/aFiling
Q1 FY24ended 30 Jun 2023 / Consolidated, auditedRs 1,021 crRs 16.53n/an/aFiling
Q4 FY23ended 31 Mar 2023 / Consolidated, auditedRs 882 crRs 9.54n/an/aFiling
Q3 FY23ended 31 Dec 2022 / Consolidated, auditedRs 972 crRs 10.50n/an/aFiling
Q2 FY23ended 30 Sep 2022 / Consolidated, auditedRs 938 crRs 12.22n/an/aFiling
Q1 FY23ended 30 Jun 2022 / Consolidated, auditedRs 951 crRs 13.63n/an/aFiling
Q4 FY22ended 31 Mar 2022 / Consolidated, auditedRs 870 crRs 17.70n/an/aFiling
Q3 FY22ended 31 Dec 2021 / Consolidated, auditedRs 838 crRs 22.16n/an/aFiling
Q2 FY22ended 30 Sep 2021 / Consolidated, auditedRs 885 crRs 22.64n/an/aFiling
Q1 FY22ended 30 Jun 2021 / Consolidated, auditedRs 748 crRs 20.08n/an/aFiling
Q4 FY21ended 31 Mar 2021 / Consolidated, auditedRs 757 crRs 18.40n/an/aFiling
Q3 FY21ended 31 Dec 2020 / Consolidated, auditedRs 749 crRs 20.41n/an/aFiling
Q2 FY21ended 30 Sep 2020 / Consolidated, auditedRs 716 crRs 19.51n/an/aFiling
Q1 FY21ended 30 Jun 2020 / Consolidated, auditedRs 668 crRs 16.93n/an/aFiling
Q4 FY20ended 31 Mar 2020 / Consolidated, auditedRs 682 crRs 14.80n/an/aFiling
Q3 FY20ended 31 Dec 2019 / Consolidated, auditedRs 651 crRs 12.33n/an/aFiling
Q2 FY20ended 30 Sep 2019 / Consolidated, auditedRs 643 crRs 13.34n/an/aFiling
Q1 FY20ended 30 Jun 2019 / Consolidated, auditedRs 612 crRs 13.14n/an/aFiling
Q4 FY19ended 31 Mar 2019 / Consolidated, auditedRs 515 crRs 10.10n/an/aFiling
Q3 FY19ended 31 Dec 2018 / Consolidated, auditedRs 485 crRs 7.60n/an/aFiling
Q2 FY19ended 30 Sep 2018 / Consolidated, auditedRs 544 crRs 14.25n/an/aFiling
Q1 FY19ended 30 Jun 2018 / Consolidated, auditedRs 511 crRs 12.02n/an/aFiling

Open the covered-name earnings calendar.

The official financialsFiled to 31 Mar 2026

AJANTA PHARMA LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.

Trailing twelve months, on filed quarters

Revenue (TTM)

5,453 cr

Net profit (TTM)

1,056 cr

EBIT (TTM)

1,394 cr

Profit before tax (TTM)

1,378 cr

Net margin (TTM)

19.4%

Finance costs (TTM)

16.1 cr

Balance sheet, as filed 2026-03-31

Total assets

6,155 cr

Shareholder equity

4,527 cr

Total borrowings

212 cr

Cash and equivalents

103 cr

Inventory

939 cr

Trade receivables

1,854 cr

The cash engine, latest filed year

Operating cash flow

529 cr

Capex

365 cr

Free cash flow

164 cr

Investing flow

429 cr

Financing flow

168 cr

Annual trail, filed year over filed year

YearRevenueNet profitEquityBorrowingsCFO
FY265,453 cr1,056 cr4,527 cr212 cr529 cr
FY254,648 cr920 cr3,790 cr2.6 cr1,157 cr
FY244,209 cr816 cr3,567 cr1.5 cr785 cr
FY233,743 cr588 cr3,388 cr1.4 cr792 cr
FY223,341 cr713 cr3,264 cr1.9 cr562 cr
FY212,890 cr654 cr2,996 cr1.6 crn/a

Every figure is parsed from AJANTA PHARMA LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.

Management on record3 earnings calls

Every AJANTPHARM earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.

AJANTA PHARMA LIMITED earnings calls on record

3 calls since 31 Aug 2022

31 May 2026Quarter ended Q4FY26Transcript PDF
31 Jan 2026Quarter ended Q3FY26Transcript PDF
31 Aug 2022Quarter ended Q1FY23Transcript PDF

Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.

What changed1 disclosure

Every recent official filing from AJANTA PHARMA LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.

AJANTA PHARMA LIMITED's most recent official filing is a Earnings dated 31 Mar 2026.

Event Heat

61 / 100
31 Mar 2026
EarningsWatch

AJANTA PHARMA LIMITED Q4 FY26 earnings result: profit_acceleration

Filing
Event Heat61 / 100 · Tilting up

Event Heat is a dated net read of AJANTA PHARMA LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.

See what changed across the whole market.

Key fundamentalsEditorial reference

The anchor data BazaarBaazi references when reading the AJANTPHARM chart. Not a substitute for a registered research note.

TickerAJANTPHARM
Full nameAJANTA PHARMA LIMITED
SectorHealthcare
Index classMID CAP
ISININE031B01049
Market-cap band~44,662 cr (indicative)
Last referenced levelInside latest show
Last session moveNot referenced this cycle
Editorial line inSystematic Read on 21 Jul 2026
Aliases trackedAJANTPHARM

Reference chartLevels in show

The daily frame the desk reads on AJANTPHARM.

Chart frame not yet rendered for AJANTPHARM. The desk references levels inline inside each show.
Structural levels are read inside the latest show.

FAQ11 reader questions · AEO-eligible

The line on AJANTPHARM, distilled and schema-marked for AI Overview, Perplexity, and reader search.

What is the AJANTPHARM share price target for 2026?

BazaarBaazi does not publish a SEBI-registered price target on AJANTPHARM. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.

What is BazaarBaazi's Crack Score for AJANTPHARM?

The BazaarBaazi Crack Score for AJANTPHARM is 89 out of 100 as of 25 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.

What is the F&O view on AJANTPHARM?

Strike-level option inventory for AJANTPHARM is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.

What sector is AJANTPHARM in and which peers does BazaarBaazi track?

AJANTPHARM sits in Healthcare (mid cap), indicative market cap ~44,662 cr (indicative), ISIN INE031B01049. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on AJANTA PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.

How often is the AJANTPHARM view updated?

This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on AJANTPHARM is bullish, published in Systematic Read on 21 Jul 2026.

Is AJANTPHARM a qualifying setup on the BazaarBaazi scanner right now?

On the 2026-07-24 run of the 500-name BazaarBaazi setup scanner, AJANTA PHARMA LIMITED sits in the Scanned tier with a setup score of 77/100 (technical 100, fundamental 33). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.

Where can I read AJANTA PHARMA LIMITED's earnings call transcripts?

BazaarBaazi indexes 3 AJANTPHARM earnings calls going back to 2022-08-31, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.

What was AJANTA PHARMA LIMITED's Q4 FY26 net profit?

AJANTA PHARMA LIMITED reported a net profit of Rs 267 cr for Q4 FY26 (the quarter ended 31 March 2026). The figure is from the company's official NSE filing.

What was AJANTA PHARMA LIMITED's Q4 FY26 revenue?

AJANTA PHARMA LIMITED reported revenue of Rs 1,422 cr for Q4 FY26. The figure is from the company's official NSE filing.

How does BazaarBaazi rate AJANTA PHARMA LIMITED's Q4 FY26 result?

BazaarBaazi gives AJANTA PHARMA LIMITED's Q4 FY26 result a Result Pulse of 0 out of 100, with a verdict of Insufficient data. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.

What has Ajanta Pharma Ltd announced recently?

The most recent official filing on record for Ajanta Pharma Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.

Related stock views

The names BazaarBaazi reads alongside AJANTPHARM, each a living view refreshed every end-of-day run.

All stock viewsAbout BazaarBaazi →